Urinary Podocyte Excretion and Proteinuria in Patients Treated with Antivascular Endothelial Growth Factor Therapy for Solid Tumor Malignancies

Publisher： Karger

E-ISSN： 1423-0232|86|5-6|271-278

ISSN： 0030-2414

Source： Oncology, Vol.86, Iss.5-6, 2014-06, pp. : 271-278

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Urinary Excretion of Vascular Endothelial Growth Factor Is Increased in Children with Reflux Nephropathy

By  

Nephron Clin Pract, Vol. 98, Iss. 3, 2004-11 ,pp. : c73-c78

Karger

Access to resources Recommend Favorite

To dry or not too dry: should we be more tolerant of stable subretinal fluid in patients receiving anti‐vascular endothelial growth factor treatment for neovascular age‐related macular degeneration?

By  

CLINICAL & EXPERIMENTAL OPHTHALMOLOGY, Vol. 43, Iss. 8, 2015-11 ,pp. : 707-710

John Wiley & Sons Inc

Access to resources Recommend Favorite

Prognostic Significance of Vascular Endothelial Growth Factor and Cyclooxygenase-2 in Patients with Rectal Cancer Treated with Preoperative Radiotherapy

By  

Oncology, Vol. 71, Iss. 5-6, 2007-08 ,pp. : 312-319

Karger

Access to resources Recommend Favorite

A phase 1 study of cetuximab and lapatinib in patients with advanced solid tumor malignancies

By  

CANCER, Vol. 121, Iss. 10, 2015-05 ,pp. : 1645-1653

John Wiley & Sons Inc

Access to resources Recommend Favorite

Single-Nucleotide Polymorphisms in the Vascular Endothelial Growth Factor Pathway and Outcomes of Patients Treated with First-Line Cytotoxic Chemotherapy Combined with Bevacizumab for Advanced Colorectal Cancer

By  

Oncology, Vol. 87, Iss. 5, 2014-08 ,pp. : 280-292

Karger

Access to resources Recommend Favorite